Stay updated with breaking news from Peter Hillmen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.
<p>Leukaemia trial shows 'exceptional' resultsPersonalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found.</p> <p>Adult patients were given a combination of cancer growth blocking drugs over varied durations depending on how rapidly their disease responded. </p> <p>More than 19 in 20 patients were in remission three years after starting treatment - a significant improvement in progression-free and overall survival compared to standard trea...
The FDA has approved the new Empaveli (pegcetacoplan) Injector, a single-use, on-body device for self-administration.
A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.
03.11.2022 - Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH)WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global ... Seite 1